Zobrazeno 1 - 10
of 482
pro vyhledávání: '"erdafitinib"'
Autor:
Maxim Noeraparast, Katarina Krajina, Renate Pichler, Dora Niedersüß‐Beke, Shahrokh F Shariat, Viktor Grünwald, Sascha Ahyai, Martin Pichler
Publikováno v:
Cancer Communications, Vol 44, Iss 10, Pp 1189-1208 (2024)
Abstract In this review, we revisit the pivotal role of fibroblast growth factor receptor 3 (FGFR3) in bladder cancer (BLCA), underscoring its prevalence in both non‐muscle‐invasive and muscle‐invasive forms of the disease. FGFR3 mutations in u
Externí odkaz:
https://doaj.org/article/9e3eb5c1f9b94eb79fa47e4b178e90be
Publikováno v:
JAAD Case Reports, Vol 54, Iss , Pp 62-65 (2024)
Externí odkaz:
https://doaj.org/article/111f8d759879463397ef43edac68a909
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Autor:
Joon Oh Park, Yin-Hsun Feng, Wu-Chou Su, Do-Youn Oh, Bhumsuk Keam, Lin Shen, Sang-We Kim, Xiufeng Liu, Huimin Liao, Min Qing, Chong Zhang, Jiaqi Qian, Xiaodan Tang, Peng Li, Spyros Triantos, Hussein Sweiti
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background FGFR genomic aberrations occur in approximately 5–10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR-altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecologica
Externí odkaz:
https://doaj.org/article/46cf37a8f4c5475998d9519b116a314e
Publikováno v:
TNOA Journal of Ophthalmic Science and Research, Vol 62, Iss 3, Pp 368-370 (2024)
Fibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of antiapo
Externí odkaz:
https://doaj.org/article/c43d1ca8762f42eebb1584eab55bb370
Autor:
Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar
Publikováno v:
Acta Pharmaceutica, Vol 74, Iss 1, Pp 1-36 (2024)
The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment. Fibroblast growth factor receptor (FGFR) gene alterations are frequent
Externí odkaz:
https://doaj.org/article/7b89aa80b68548bb8237cfaba3aee2c1
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 34, Iss , Pp 102028- (2024)
Purpose: This report aims to highlight the wide spectrum of ophthalmic adverse events associated with erdafitinib, a fibroblast growth factor inhibitor that blocks activation of the mitogen-activated protein kinase kinase (MAPK/MEK) cascade. The purp
Externí odkaz:
https://doaj.org/article/2113b404f2e24d0881b60b7f741e8327
Publikováno v:
European Journal of Case Reports in Internal Medicine (2024)
Background: A case of bilateral multifocal serous retinal detachments and dry eye complicated with unilateral peripheral ulcerative keratitis (PUK) during erdafitinib therapy is described. Case description: A 76-year-old male underwent a baseline exa
Externí odkaz:
https://doaj.org/article/aa8b9ad7fe5f4898aca6cfc0afca3fcf
Autor:
Meziane Brizini, Tina Drimes, Catherine Bourne, Jessica Streilein, Annie Drapeau, Jens Wrogemann, Lori Anne Archer, Marc Del Bigio, Magimairajan Issai Vanan
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
We report a case of slipped capital femoral epiphysis (SCFE), an on target skeletal toxicity of a pan-FGFR TKI inhibitor, erdafitinib. A 13-year-old boy was diagnosed to have an optic pathway/hypothalamic glioma with signs of increased intracranial p
Externí odkaz:
https://doaj.org/article/2a4b350bfc4e45eaa1ac23189336a05c
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/a4084586bc1f442cb1a630e30a4b1a5b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.